

DT09 PCT/PTO 23 AUG 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	National Phase Entry of PCT/EP03/01809
Filing Date	Herewith 10/505482
First Named Inventor	STREBHARDT et al
Group Art Unit	
Examiner Name	

Sheet	1	of	2	Attorney Docket Number	2923-656
-------	---	----	---	------------------------	----------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
SW	1.	6,183,961	B1	Harold S. Bernstein et al	2/6/01

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			

Examiner
Signature

Louis Dollenberger

Date
Considered

4/21/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete Known	
				Application Number	National Phase Entry of PCT/EP03/01809
				Filing Date	Herewith 10/505482
				First Named Inventor	STREBHARDT et al
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	2923-656
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
SW	2.	Wolf et al., "Inhibition of tumor cell proliferation in vitro by antisense oligonucleotides directed against the serine-threonine-kinase PLK", PATHOLOGY RESEARCH AND PRACTICE, vol. 196, no. 6, 7 June 2000, pg. 352			
SW	3.	Wolf et al., "Antitumor activity of an antisense oligodeoxynucleotide targeted against human polo-like kinase PLK", INT. J. OF MOLECULAR MEDICINE, vol. 6, no. supp., - 2000 page s80.			
SW	4.	Yuan et al., "Polo-like kinase, a novel marker for cellular proliferation", AM. J. Pathol., vol. 150, no. 4, April 1997, pgs. 1165-1172.			
SW	5.	Thompson, "Applications of antisense and siRNAs during preclinical drug development", DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD, vol. 7, no. 17, 1 September 2002, pgs. 912-917.			
SW	6.	Tuschl, "RNA interference and small interfering RNAs", CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, vol. 2, no. 4, April 2001, pgs. 239-245.			
SW	7.	Spaenkuch-Schmitt et al., "Inhibition of polo-like kinase 1 by antisense oligonucleotides and RNA interference", EUROPEAN J. OF CANCER, vol. 38, no. supp7, 22 November 2002, page s144.			
Examiner Signature	Louis Wollenberger			Date Considered	11/21/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.